Lipisense

N/A

Report date: 2023/12/25 16:28:56
NME

Base Information

Drug NameLipisense
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionAnti-Angiopoietin-related protein 4
TargetsAngiopoietin-related protein 4
Therapy Area/IndicationsHypertriglyceridemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLipigon Pharmaceuticals ABSecarna Pharmaceuticals GmbH & Co KG
China Registration ClassN/A

Develop Information

Active CompaniesLipigon Pharmaceuticals AB
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A